Aytu BioPharma (AYTU) Q3 2026 earnings review
The Painful but Necessary Pivot: EXXUA Ramps as ADHD Collapses
Aytu is crossing a precarious financial bridge. Total revenue declined 33% YoY to $12.4M as its legacy cash cow, the ADHD portfolio, saw revenues collapse 41% following generic competition and a shift in sales force focus. This transition dragged Adjusted EBITDA into negative territory for a second consecutive quarter. However, the bull case rests entirely on the other side of this bridge: the newly launched EXXUA generated $2.4M in its first partial quarter, showing strong early adoption metrics in a $22 billion MDD market. The story here is pure transition—the legacy business is eroding faster than EXXUA is growing today, but EXXUA's ceiling is significantly higher.
🐂 Bull Case
The major depressive disorder (MDD) drug generated $2.4M in its first partial quarter of full sales support. With over 1,300 prescriptions written by 450+ unique prescribers, early adoption and titration pack refills validate the clinical differentiation strategy.
Aytu resolved the accounting ambiguity around its warrants, reclassifying $26.4M in derivative liabilities to equity. This removes the massive, non-cash P&L swings that obscured operational performance in prior quarters.
🐻 Bear Case
The generic threat to Adzenys XR-ODT has materialized with punishing speed. The ADHD portfolio fell 41% YoY, removing the primary funding source for the EXXUA launch just as commercial investments are peaking.
Gross margins decelerated sharply from 69% to 61% YoY, battered by lower ADHD volumes failing to absorb fixed costs and a $0.7M inventory write-down for legacy branded products.
⚖️ Verdict: ⚪
Neutral. Management executed the highly anticipated EXXUA launch well, but the legacy business is deteriorating faster than expected. The company has $26.7M in cash to bridge the gap, but execution over the next two quarters is critical before cash burn becomes an existential concern.
Key Themes
EXXUA Launch Validates Strategic Pivot
The entire investment thesis hinges on EXXUA, and early data is encouraging. Made commercially available in mid-December 2025 and formally launched mid-January 2026, the drug generated $2.4M. Sales to channel partners (3,200 units) outpaced actual prescriptions (1,300+), indicating healthy channel stocking to meet expected compounding demand. If repeat refill rates hold, the $22 billion MDD TAM provides ample runway.
The ADHD Cliff Is Steeper Than Anticipated
In prior quarters, management consistently downplayed the threat of a generic Adzenys entrant, citing their proprietary RxConnect platform's ability to retain scripts. That narrative is reversing. Q3 ADHD revenue plummeted 41% YoY to $9.1M, citing generic competition and the intentional redeployment of the sales force. The structural integrity of this cash cow is breaking down.
Gross Margin Squeeze
Gross profit decelerated noticeably, dropping to 61% of net revenue compared to 69% a year ago. A major red flag: Aytu recorded a $0.7M inventory write-down for Adzenys branded products as they shifted focus to authorized generics. As high-margin ADHD branded revenue evaporates, overall corporate margins will remain pressured until EXXUA reaches massive scale.
Pediatric Portfolio Collapse
The pediatric segment is effectively fading into irrelevance, plunging 71% YoY from $3.1M to $0.9M. Management attributes this to payer changes impacting prescribing and an increase in product returns. This segment is no longer a viable secondary support pillar for the company.
Derivatives Noise Eliminated
A major headache for evaluating Aytu's true earnings power was the wild non-cash swings tied to its derivative warrant liabilities (e.g., an $8.2M loss in 26Q2). By amending these warrants on March 31, 2026, Aytu reclassified $26.4M from liabilities to equity, cleaning up the P&L and increasing stockholders' equity from $14.2M to $35.1M in a single quarter.
Other KPIs
Accelerating. Total operating expenses increased from $10.4M a year ago. Selling and marketing rose 14% YoY to $5.9M as the company deployed heavy planned investments to support the EXXUA field force. G&A also increased by 21% to $5.0M.
Stable but draining. Down from $30.0M at the end of December 2025. With an Adjusted EBITDA burn of $(2.8)M this quarter, the liquidity runway remains adequate, but the margin of safety shrinks if EXXUA's revenue ramp does not offset the rapidly declining ADHD cash flows in the next 3-4 quarters.
Guidance
Management refrains from hard forward numerical guidance, but explicitly communicated that resources are strategically transitioning to EXXUA as the primary growth catalyst going forward. The expectation is that EXXUA will capture share in a $22 billion MDD market, compensating for the acknowledged persistent decline in the legacy portfolio.
Key Questions
ADHD Floor
ADHD revenue dropped roughly $4 million sequentially. How quickly do you expect the generic erosion curve to flatten, and what is the baseline revenue assumption for the ADHD portfolio going forward?
EXXUA Gross-to-Net Dynamics
With 1,300+ EXXUA prescriptions yielding $2.4M in net revenue (which includes channel stocking), what are the current gross-to-net assumptions, and how do you expect payer coverage to evolve over the next two quarters?
Pediatric Portfolio Strategic Alternatives
Given the pediatric segment generated under $1 million this quarter and suffered from increased returns, are you actively exploring divesting or winding down this business to further streamline OpEx?